10-Q: Marker Therapeutics Narrows Q3 Loss, Faces Going Concern

Marker Therapeutics reported a reduced net loss for the third quarter of 2025, driven by decreased R&D expenses, while also highlighting positive clinical data from its APOLLO study and securing new manufacturing partnerships amidst a 'going concern' warning.

Summary

• Net loss for the three months ended September 30, 2025, decreased to $2.0 million from $2.3 million in the prior year period.
• Net loss for the nine months ended September 30, 2025, increased to $10.5 million from $6.9 million in the prior year period.
• Research and development expenses decreased by 32% to $2.3 million for the three months ended September 30, 2025, but increased by 15% to $9.7 million for the nine months ended September 30, 2025.
• Grant income decreased by 36% to $1.2 million for the three months and by 44% to $2.4 million for the nine months ended September 30, 2025.
• Cash, cash equivalents, and restricted cash stood at $18.9 million as of September 30, 2025.
• The company anticipates being able to fund operations through the third quarter of 2026, assuming no additional grant funds are received.
• Positive clinical data from the Phase 1 APOLLO study for MT-601 in lymphoma patients showed objective responses in 66% of NHL patients (50% CR) and 78% of HL patients (11% CR), with a favorable safety profile.
• Entered into a Statement of Work with Cellipont Bioservices for MT-601 manufacturing to support the APOLLO study and future commercial scale.
• Raised $9.9 million in net proceeds from At The Market (ATM) common stock sales in July and August 2025.

Sentiment

Score: 4

Explanation: While the company reported positive clinical data and successfully raised capital, the significant increase in net loss for the nine-month period, increased cash burn from operations, and the explicit 'going concern' warning indicate substantial financial challenges and high operational risk. The positive clinical results are promising but are still in early stages and do not offset the immediate financial concerns.

Positives

• Net loss for the three months ended September 30, 2025, decreased to $2.0 million from $2.3 million in the prior year period.
• Research and development expenses decreased by 32% for the three months ended September 30, 2025, indicating cost management.
• The Phase 1 APOLLO study for MT-601 in lymphoma patients demonstrated a favorable safety profile with no immune effector cell-associated neurotoxicity syndrome (ICANS) and only two reported Grade 1 cytokine release syndrome (CRS) events.
• Efficacy data from the APOLLO study showed objective responses in 66% of Non-Hodgkin Lymphoma (NHL) patients (50% complete response) and 78% of Hodgkin Lymphoma (HL) patients (11% complete response).
• Durable responses were observed in NHL patients, with 5 showing continued response over 6 months and 3 over 12 months.
• Secured a manufacturing partnership with Cellipont Bioservices for MT-601, supporting scale-up for the APOLLO study and future commercial production.
• Successfully raised $9.9 million in net proceeds through At-The-Market (ATM) common stock sales in July and August 2025.
• Cash, cash equivalents, and restricted cash at the end of the period (September 30, 2025) were significantly higher at $18.9 million compared to $9.0 million in the prior year period.
• The first patient was treated in the Off-the-Shelf (OTS) program on October 6, 2025, with encouraging preliminary safety data, offering a fast treatment option for rapidly progressing diseases.

Negatives

• Net loss for the nine months ended September 30, 2025, increased significantly to $10.5 million from $6.9 million in the prior year period.
• Grant income decreased by 44% for the nine months ended September 30, 2025, impacting overall revenue.
• Research and development expenses increased by 15% for the nine months ended September 30, 2025, reflecting higher program costs.
• Incurred a $453,135 loss on the early termination of a vendor agreement with Cell Ready.
• Net cash used in operating activities increased to $10.1 million for the nine months ended September 30, 2025, from $6.2 million in the prior year period, indicating higher cash burn.
• The company has a substantial accumulated deficit of $457.5 million as of September 30, 2025.

Risks

• Substantial doubt exists regarding the company's ability to continue as a going concern, as it expects to incur significant losses and requires additional capital.
• The company's ability to fund operations beyond Q3 2026 is dependent on raising additional capital and securing new grant funds, which are not assured.
• High inflation and concerns about an economic recession could reduce the company's ability to access capital and negatively affect liquidity and stock value.
• Inadequate funding or disruptions at government agencies like the FDA, SEC, and NIH (e.g., government shutdowns) could delay product development, regulatory approvals, and grant funding.
• A federal government shutdown (as of September 30, 2025) could significantly impact the FDA's ability to review regulatory submissions and NIH's budget, adversely affecting operations and clinical trials.
• Uncertainty regarding potential modifications to FDA and other regulatory agency requirements and policies by a new administration could create challenges or increase costs.
• The company has not generated revenue from product sales or licensing and does not expect to for several years, relying heavily on grants and capital raises.
• Future funding requirements are substantial and depend on factors like initiating/continuing clinical trials, R&D, regulatory approvals, manufacturing, commercialization, and strategic transactions.
• Raising additional capital through equity or convertible debt will dilute existing stockholders' ownership interests.
• Incurring indebtedness could lead to increased fixed payment obligations and restrictive covenants.
• Reliance on third-party manufacturers (Cellipont) carries risks regarding capacity, timelines, and meeting demands.

Future Outlook

The company expects to continue incurring substantial losses during its development phase. It anticipates being able to fund operating expenses and capital expenditure requirements through the third quarter of 2026, assuming no additional grant funds are received. Management is considering raising additional capital through securities issuance and applying for more grant funds to extend this runway beyond Q3 2026. Future funding needs are dependent on the progress of clinical trials, R&D, regulatory approvals, manufacturing scale-up, and potential commercialization efforts. The company is assessing the impact of the recently enacted One Big Beautiful Bill Act (OBBBA) on its tax provisions.

Management Comments

• "We anticipate that we will continue to incur net losses in the future as we continue to invest in research and development activities, including clinical development of our MAR-T cell product candidates."
• "Based on our lack of recurring revenues, anticipated uses of cash and historical recurring cash losses from operating activities, and cash, cash equivalents, and restricted cash as of September 30, 2025... we anticipate that we will be able to fund our operating expenses and capital expenditure requirements through the third quarter of 2026, assuming no additional grant funds are received, either from new grants or from existing awarded grants."
• "We are considering raising additional capital through the issuance of securities and intend to apply for additional grant funds, which could enable us to fund our operating expenses and capital expenditure requirements beyond the third quarter of 2026, although no assurance can be given that such capital or existing awarded grants will be earned or future grants will be awarded."
• "Our assumptions may prove to be wrong, and we could utilize our available capital resources sooner than we currently expect."
• "Our management, including our Chief Executive Officer and Principal Financial and Accounting Officer, believes that our disclosure controls and procedures and internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives and are effective at the reasonable assurance level."

Industry Context

Marker Therapeutics operates in the highly competitive and capital-intensive immuno-oncology and cell therapy sector, focusing on non-engineered T-cell therapies. The company positions its Multi-Antigen Recognizing (MAR)-T cell technology as potentially superior to CAR-T therapies due to its multi-target approach, favorable safety profile (no ICANS/SAEs reported), and reduced manufacturing complexity and cost. The positive Phase 1 APOLLO study results for MT-601 in lymphoma patients, including durable responses and good safety, are significant in a field where CAR-T therapies have shown efficacy but also notable toxicities. The move to partner with Cellipont Bioservices for manufacturing indicates a strategic step towards scaling up production, a common challenge in cell therapy development. The development of an Off-the-Shelf (OTS) program for AML/MDS also aligns with industry efforts to create more accessible and rapid cell therapy options.

Comparison to Industry Standards

• The filing highlights that MAR-T cells have shown "no treatment-related side effects, including immune effector cell-associated neurotoxicity syndrome (ICANS) or other severe adverse effects (SAEs)" in studies, which contrasts favorably with some CAR-T therapies (e.g., Kymriah, Yescarta) that have black box warnings for CRS and neurological toxicities, including ICANS.
• The reported two Grade 1 cytokine release syndrome (CRS) events (fever; no treatment required) in the APOLLO study for MT-601 are significantly milder than the Grade 3 or higher CRS and ICANS events often seen with CAR-T therapies, suggesting a potentially safer profile for MAR-T cells.
• The efficacy rates of 66% objective response (50% CR) in NHL and 78% objective response (11% CR) in HL patients in the Phase 1 APOLLO study are promising, especially for patients who have relapsed following anti-CD19 CAR-T cell therapy or for whom CAR-T cells are not an option, positioning MT-601 as a potential alternative in a challenging patient population.
• The company's claim of "reduced manufacturing complexity" and "lower cost" for its non-genetically engineered T-cell approach, compared to CAR-T, addresses a major industry challenge where high manufacturing costs and logistical complexities are significant barriers to broader adoption.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any legal proceedings that could have a material adverse effect on the business, operating results, or financial condition.

Related Party Transactions

• Baylor College of Medicine (BCM): Incurred $2.9 million in expenses for services and manufacturing costs during the nine months ended September 30, 2025. BCM is a licensor of technology and a shareholder.
• Cell Ready, LLC: Incurred $1.1 million in expenses for services and manufacturing costs during the nine months ended September 30, 2025. The Master Services Agreement was terminated on March 27, 2025, with a settlement payment of approximately $453,000. Cell Ready is owned by a former director, Mr. John Wilson.
• Wilson Wolf Manufacturing Corporation: Incurred approximately $67,000 in expenses for cell culture devices during the nine months ended September 30, 2025. Mr. John Wilson, a former director, is the CEO of Wilson Wolf.

Stakeholder Impact

• Shareholders: Dilution from recent ATM sales and potential future capital raises. Risk of significant value loss due to 'going concern' doubt. Potential for long-term gains if product candidates achieve regulatory approval and commercial success.
• Employees: Continued employment and potential for stock-based compensation, but uncertainty due to financial condition and need for future funding.
• Customers (future): Potential for novel T-cell immunotherapies for hematological malignancies and solid tumors, offering new treatment options with potentially better safety profiles than existing therapies.
• Suppliers/Creditors: Risk of delayed or non-payment due to the company's 'going concern' status and reliance on future capital raises.
• Grant Funding Agencies: Continued investment in promising research, but also subject to revenue-sharing agreements if products are commercialized.

Next Steps

• Commencement of a larger pivotal trial for Lymphoma in 2026.
• Continue research and development of product candidates and seek to discover additional candidates.
• Seek regulatory approvals for product candidates that successfully complete clinical trials.
• Maintain and enforce intellectual property rights.
• Enter into contract manufacturing arrangements with contract manufacturing organizations for clinical manufacturing supply.
• Establish sales, marketing, and distribution infrastructure and scale-up manufacturing capabilities for commercialization.
• Evaluate strategic transactions the company may undertake.
• Enhance operational, financial, and information management systems and hire additional personnel.
• Management intends to apply for additional grant funds.
• Management is assessing the potential impact of the One Big Beautiful Bill Act (OBBBA) on its financial statements.

Key Dates

Recommendation

The explicit "substantial doubt regarding the company's ability to continue as a going concern" is a critical red flag for investors. While positive clinical data for MT-601 is encouraging, it is still in early stages (Phase 1) and does not guarantee future success or commercialization. The significant increase in net loss and cash burn for the nine-month period, coupled with declining grant income, highlights persistent financial challenges. Although recent capital raises provide a short-term runway until Q3 2026, the continuous need for additional funding and the inherent risks of clinical development in a capital-intensive industry make the stock highly speculative and vulnerable to further dilution or financial distress. A seasoned investor would likely view the going concern warning as a strong reason to exit or avoid the stock, despite the clinical progress.

Keywords

Immuno-oncology, T-cell therapy, MAR-T cell, MT-601, MT-401-OTS, Lymphoma, Pancreatic cancer, Acute Myeloid Leukemia (AML), Clinical trial, APOLLO study, Cellipont Bioservices, Biotechnology, Pharmaceutical, SEC filing, 10-Q, Going concern, Capital raise, Grant funding